The Penn Center for Cancer Care Innovation is thrilled to announce that PC3I Fellow Anna Jo Smith, MD, MPH, MSc has earned a Young Investigator Award from Conquer Cancer, the ASCO Foundation. The award provides funding to promising investigators as they transition from fellows to faculty.
Dr. Smith will focus on improving care delivery for patients with adnexal masses and suspected ovarian cancer. Ovarian cancer is among the deadliest of gynecologic cancers and currently lacks effective screening. While survival improves with surgical evaluation by a gynecologic oncologist, chemotherapy, and/or targeted cancer drugs called PARP inhibitors, many patients do not receive these treatments. Therefore, to increase patient participation in the previously mentioned treatments and reduce care disparities that start at diagnosis, Dr. Smith is testing the implementation of a default clinician-directed opt-out nudge to improve referral to gynecologic oncology for patients with suspected ovarian cancer, with a particular focus on patients from historically marginalized populations. The study will be conducted over a 12-month period and will examine the effect of clinician nudges compared with usual care.
iNUDGE Initiative Partners with Loxo@Lilly to Improve Personalized Medicine for People with Lung Cancer
In collaboration with Loxo@Lilly, PC3I Associate Director Charu Aggarwal is leading the "iNUDGE' initiative to improve personalized care for people with lung cancer.
Penn Medicine Princeton Health Receives $2.5M to Establish Geriatric Oncology Program Led by PC3I Faculty Ramy Sedhom
A $2.5 million gift from the Bristol Myers Squibb Foundation will help establish a Geriatric Oncology Program to improve care for older adults with cancer at the Penn Medicine Princeton Cancer Center.
PC3I Faculty Oluwadamilola "Lola" Fayanju Leading Innovative Collaborative Research Initiative with Gilead Sciences
PC3I Associate Director Lola Fayanju is leading a collaborative research initiative with Gilead Sciences to optimize collection of SBDoH from patients with breast cancer.